The role of cell competition in shaping the clonal structure of hematopoiesis
Active Grant Awarded
- Award ID
- R01CA317504
- Recipient
-
The Washington University UEI L6NFUM28LQM5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $465,749
Award facts
- Assistance listing
- 93.396 Cancer Biology Research
- Completion date 4% complete
- Place of performance
- St. Louis, MO 63110, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded The Washington University, Office of Sponsored Research Services, $465,749 obligated on September 9, 2026, under Cancer Biology Research (CFDA 93.396) through grant R01CA317504. The award funds research on how cell competition shapes the clonal structure of hematopoiesis. The project examines how clonal hematopoiesis clones in human bone marrow support or inhibit one another depending on context. Its focus is myeloproliferative neoplasm (MPN) disease progression. Single-cell sequencing of paired patient samples shows that progression mutations can arise in clones separate from the MPN cells, and mouse and human model data show MPN-secreted cytokines selecting for parallel clones with TET2 mutations. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2031. Place of performance is St. Louis, MO 63110, USA. The Cancer Biology Research program supports fundamental research on the cause and nature of cancer, and this award falls within its cancer immunology, hematology and etiology area.
Description
- Abstract
- All humans become genetic mosaics over time as somatic stem cells acquire mutations throughout life. In the hematopoietic compartment, this phenomenon is termed clonal hematopoiesis (CH) when the mutations provide a competitive advantage to those stem cells. The mutations observed in CH overlap with blood diseases. But while the prevalence of CH is universal, risk of disease progression from CH is highly variable. While we know some of the risk factors, one concept that has not been considered in risk prediction models is the influence of the surrounding environment. Human bone marrow becomes a complex genetic milieu with age with CH clones potentially influencing the development of other clones, both in positive and negative ways. Due to the low mutant cell burden in many CH carriers, interaction of clones is difficult to study in humans. But our recent lab studies have indicated that particular clones can support or inhibit other CH mutations depending on the context. One such example is the focus of this proposal. Myeloproliferative neoplasms (MPNS) are chronic hematological diseases driven by mutations acquired in hscs. In up to 20% of patients, MPN undergoes disease progression which dramatically changes the prognosis for these patients. The classical dogma of disease progression in MPN patients is whereby the MPN clones acquire additional cooperating mutations. But our new singlecell sequencing data from paired patient samples shows the mutations that arise during disease progression can occur in separate clones distinct from the MPN cells. Thus, in such patients the more accurate diagnosis is two separate blood diseases evolving in parallel. Data from our mouse and human model systems show a mechanism of clonal support whereby cytokines secreted by the MPN cells act as an evolutionary pressure that selects for parallel CH clones with TET2 mutations. Here, we will dissect the cell-intrinsic and cell-extrinsic mechanisms that drive these evolutionary processes with the ultimate goal of developing novel interventions to prevent disease progression in MPN patients. This will be accomplished via the following specific aims: - specific aim 1: identify characteristics of PV cells that provide selective pressures for TET2-mutant clones. - specific aim 2: develop interventions to mitigate outgrowth of TET2-mutant clones in an MPN background. Disease progression in MPN remains a significant health problem that requires study in pre-clinical models. Mice are used for these in vivo studies because hematopoietic maintenance and evolution can only be studied in the context of an intact animal. We choose to do this work with mouse models because the hematopoietic system of the mouse is very similar to that of humans. We have generated novel mouse strains to recapitulate the genetics of human disease and will complement this with our technical expertise in patient-derived xenografts (PDXS) using primary human specimens in immunodeficient mice to rigorously execute these studies. We will use a combination of singlecell approaches, genetic mouse models and our unique MPN PDX system to study the importance of clonal competition in shaping the clonal structure of hematopoietic development.
Quick answers
Who received award R01CA317504?
R01CA317504 was awarded to The Washington University by National Cancer Institute (National Institutes of Health) on September 9, 2026.
How much is award R01CA317504 worth?
$465,749 has been obligated on R01CA317504.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award